Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US8021856B2 · kind B2 · utility
22Cited by
16References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2005 |
| Grant date | Sep 20, 2011 |
| Priority date | — |
| Expiry date | Mar 21, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.